BTK Inhibitors in Relapsed/Refractory CLL
Read More
MURANO Trial Update in R/R CLL
Read More
Utility of MRD Testing in CLL Management
Read More
Venetoclax Combinations, Safety and Efficacy
Read More
Venetoclax and Obinutuzumab in CLL
Read More
Novel Therapies for Relapsed/Refractory CLL
Read More
Relapsed/Refractory CLL: Treatment Selection
Read More
BTK inhibitor With vs Without a CD20-Targeted Antibody
Read More
Second-Generation BTK Inhibitors in CLL
Read More
Therapies in the Pipeline for Frontline CLL
Read More
Telemedicine for Patients With CLL
Read More
BTK Inhibitors in CLL: Ibrutinib
Read More
Current Role for Chemoimmunotherapy in CLL
Read More
Frontline Treatment Options in CLL
Read More
Selecting Frontline Therapy for CLL
Read More
COVID-19 and CLL Treatment Initiation
Read More
Selecting First-Line Therapy for CLL
Read More
Advances in Frontline Therapy for CLL
Read More
Impact of COVID-19 on Management of CLL
Read More
Initial Work-up for Chronic Lymphocytic Leukemia
Read More
Dr. Shadman on the Efficacy of Venetoclax in CLL
August 20th 2019Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the efficacy of venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).
Read More
Dr. Shadman on the CLL14 Trial in CLL
July 19th 2019Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, University of Washington School of Medicine, and attending physician, Hematologic Malignancies, Seattle Cancer Care Alliance, discusses the phase III CLL14 trial in chronic lymphocytic leukemia (CLL).
Read More
Dr. Shadman on Fixed Durations of Treatment in CLL
July 9th 2019Mazyar Shadman, MD, MPH, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, assistant professor, Medical Oncology Division, Department of Medicine, University of Washington School of Medicine, and attending physician, Seattle Cancer Care Alliance, discusses fixed durations of treatment in chronic lymphocytic leukemia (CLL).
Read More